Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Inflammatory biomarkers predict well-being in elderly patients with AML

05 Apr 2020

Inflammatory biomarkers, such as interleukin-6 (IL-6), IL-6 soluble receptor (sR), C-reactive protein (CRP) and tumour necrosis factor alpha (TNFα), appear to correlate with physical and mental health in elderly patients with acute myeloid leukaemia (AML), a recent study has shown.

The study included 20 elderly AML patients (median age, 68.3 years; 55 percent female) who underwent Geriatric Assessment (GA) at baseline and at 4 weeks after discharge. Blood samples were drawn and subjected to cytokine assays for the measurement of inflammatory biomarker. Outcomes included changes in GA and in biomarker levels, complete remission, and overall survival.

Higher distress at baseline was correlated with elevated TNFα sR1 (p=0.04) and CRP (p=0.04) levels. No other biomarker had such significance at baseline.

Over the duration of follow-up, increasing blood concentrations of TNFα sR1 was associated with self-reported limitations in instrumental activities of daily living (p<0.01) and worsening physical function (p<0.01), as objectively measured by the short physical performance battery (SPPB). Spikes in CRP were likewise inversely correlated with SPPB (p<0.01).

IL-6 sR, on the other hand, was directly correlated with improvements in depressive symptoms (p=0.02).

In terms of AML outcomes, high TNFα was linked to significantly shorter median survival (p=0.04), as was high baseline CRP (p=0.04). No other biomarker correlated with survival.

“The role of TNFα and CRP as biomarkers to predict survival in older patients with AML receiving induction chemotherapy should be confirmed in larger studies,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.